June 25, 2026 was a very good day for preemption. While one hand of the judiciary was busy with the Supreme Court handing down its 7-2 ruling in Monsanto Co. v. Durnell — establishing that FIFRA expressly preempts Roundup state-law failure-to-warn claims, the other hand was quietly doing the same thing with toothpaste. Specifically, the
Prescription in All But Name: Illinois Reverses Multi-Million Dollar Baby Formula Verdict Under the Learned Intermediary Doctrine
Baby formula is not a prescription drug. No doctor hands you a slip of paper for it. The FDA does not regulate it that way. And yet — when a premature newborn receives cow-milk-based preterm formula through a tube in a neonatal intensive care unit, administered by hospital staff, ordered by neonatologists, selected after individualized
Evidence of Retention Is Not Evidence of Causation: Oklahoma Affirms Summary Judgment in Gadolinium Case
Gadolinium is a heavy metal. Sounds ominous. But it is also the active component in contrast agents used in more than 100 million MRI procedures — and its accumulated safety record is, in the words of plaintiff’s own literature, “extraordinarily positive.” Combs v. Bayer AG, 2026 WL 1693470, at *11 n.19 (Okla. App. Ct.
Comment k Takes a Hit in the Covidien Mesh MDL
A few weeks ago, we found ourselves underwhelmed by the court’s Rule 702 rulings in the Covidien Hernia Mesh MDL. Today, we can say much the same thing about its summary judgment decision. In In re: Covidien Hernia Mesh Products Liability Litigation No. II, 2026 WL 1555914 (D. Mass. June 2, 2026), the
Product Representatives are Not Surgical Supervisors: No Duty to Grab the Scalpel
Medical device sales representatives are many things. They know their product lines inside and out. They can tell a surgeon exactly where to find a particular screw, rod, or connector in a tray containing dozens of components. They can help ensure the requested hardware is available when needed. What they cannot do is scrub in
“Shall Not Be Used” Means Shall Not Be Used
The court in In re Acetaminophen—ASD-ADHD Products Liability Litigation confronted a problem that should not have existed in the first place–plaintiffs’ co-lead counsel violating confidentiality and coordination orders that he had helped negotiate.
The underlying orders were straightforward. The MDL confidentiality order protected confidential and highly confidential information produced in the litigation and prohibited the
Summary Judgment Twenty Years in the Making
Back in 2006, people were still carrying around Motorola Razrs, “YouTube” was barely a year old, and nobody had heard of an iPhone. That is when the device in Aceste v. Stryker Corp., 2026 Ohio Misc. LEXIS 1215 (Lucas Cty. C.P. Feb. 4, 2016),was implanted. By the time the case was filed in 2015
Hernia Mesh MDL Lets Causation In But Draws the Line at Ipse Dixit
If Rule 702 is supposed to keep unreliable expert opinions out, this decision raises a fair question: how many gaps are too many? In In re Covidien Hernia Mesh Products Liability Litigation, 2026 WL 1129617 (D. Mass. Apr. 27, 2026), the court considered a familiar lineup of expert opinions—general causation, specific causation, alternative design
When Choice of Forum Has No There There
This post is from the non-Reed Smith side of the blog.
If you’re going to forum shop, you still need a legitimate forum. That was the problem for plaintiffs in Rodriguez v. Thoratec Corp., 2026 U.S. Dist. LEXIS 88964 (N.D. Cal. Apr. 20, 2026). Texas and Arkansas residents brought suit in California over an
Res Ipsa Loquitor Can’t Save Benzene Class Action
Benzene-based consumer class actions are becoming almost routine. So are their dismissals on preemption grounds. It takes something a little different to make one stand out. The plaintiff in Leonard v. CVS Pharmacy, 2026 WL 986311 (N.D. Cal. Apr. 13, 2026), tried just that, invoking a res ipsa loquitur–type theory to plead “parallel”